Cytovance Biologics & PolyPeptide Partner on Peptide Drug Development

Cytovance Biologics and PolyPeptide Forge Strategic Partnership for Peptide Drug Development

Calif. — In response to the increasing demand for peptide-based therapies, Cytovance Biologics and PolyPeptide have announced an exciting collaboration aimed at enhancing the development and manufacturing of microbial and mammalian-expressed peptide drugs. This partnership combines the strengths of Cytovance’s experience in microbial and mammalian expression systems, process development, and cGMP manufacturing with PolyPeptide’s renowned expertise in complex peptide synthesis and development.

This collaboration is designed to provide customers with an integrated, scalable solution for the outsourcing of peptide drug development and production. Whether it’s for small-scale research or large-scale commercial manufacturing, the two companies are committed to offering a comprehensive range of services to meet the evolving needs of the peptide drug market.

A Strategic Alliance to Meet Growing Peptide Demand

Cytovance Biologics & PolyPeptide,Peptide drugs have garnered significant attention due to their therapeutic potential in treating a wide range of diseases, from cancers to metabolic disorders. As the global peptide drug market continues to expand, drug developers are increasingly seeking reliable partners to help accelerate their product development timelines and ensure the highest quality production standards.

Cytovance Biologics & PolyPeptide with two decades of experience in biologics development, is well-established in the areas of microbial and mammalian expression. The company has a proven track record of providing high-quality process development, scalable manufacturing, and regulatory support to meet cGMP requirements.

PolyPeptide, on the other hand, is a leader in the development and synthesis of complex peptides. With over 1,000 therapeutic Cytovance Biologics & PolyPeptide manufactured, PolyPeptide’s deep knowledge of peptide chemistry and production processes has made it a trusted partner for companies seeking innovative solutions for drug development.

By combining these complementary capabilities, the partnership between Cytovance and PolyPeptide offers drug developers access to a comprehensive and streamlined approach to peptide manufacturing — from early-stage development to clinical-scale production and commercialization.

Expertise and Innovation Driving Industry Advancement

Axel Schleyer, Chief Commercial Officer (CCO) of Cytovance Biologics, emphasized the importance of this partnership in addressing the industry’s evolving needs. “Cytovance has been supporting the development and scale-up of microbial and mammalian-expressed biologics for two decades. Combining our strengths with PolyPeptide’s is exactly what our customers and the industry need to support the rapidly advancing market demand,” Schleyer said.

Cytovance Biologics & PolyPeptide combined expertise in drug development and manufacturing ensures that peptide drugs are produced with the highest level of precision and efficiency. Cytovance’s long-standing commitment to cutting-edge process development, cGMP-compliant manufacturing, and quality assurance processes positions it as a trusted partner for companies looking to bring their peptide-based therapies to market.

Trishul Shah, Director of Business Development at PolyPeptide, added: “With a track record of over 1,000 therapeutic peptides manufactured, PolyPeptide offers deep peptide development and synthesis capabilities. The collaboration gives customers access to complementary technology portfolios to drive their innovative drug development projects.” Shah’s statement highlights the strength of PolyPeptide’s diverse capabilities in peptide drug production, which include peptide synthesis, purification, and advanced analytical testing.

A Partnership Built on Success

While this new collaboration marks a major milestone in the relationship between Cytovance and PolyPeptide, the two companies have previously worked together on specific customer projects. The expansion of their partnership now allows them to offer a broader range of services, including enhanced capacity, rapid ramp-up times, and increased production efficiency. These factors will be instrumental in helping drug developers meet the growing demand for peptide therapies and bring new drugs to the clinic faster.

The partnership is poised to help overcome some of the key challenges faced by drug developers in the peptide space. For instance, the scaling up of production to meet clinical and commercial demand can be a complex and time-consuming process. With Cytovance’s expertise in both microbial and mammalian expression platforms, along with PolyPeptide’s advanced peptide synthesis and purification technologies, customers can expect faster development timelines, reduced costs, and a more streamlined path to market.

Meeting the Needs of the Peptide Market

Peptide-based therapies are seeing a surge in popularity due to their specificity, safety profiles, and ability to target complex biological mechanisms. However, developing and manufacturing these drugs can be challenging, requiring specialized knowledge and advanced technologies. The collaboration between Cytovance Biologics and PolyPeptide addresses these challenges head-on, providing a seamless solution for drug developers looking to navigate the complexities of peptide drug development.

The partnership is designed to cater to both small biotech startups and large pharmaceutical companies, offering scalable solutions that meet diverse production needs. Whether customers require initial development services or full-scale cGMP manufacturing, Cytovance and PolyPeptide’s combined capabilities offer a versatile and reliable option.

Source link

Share your love